構造に関する研究,性能,修飾およびヒアルロン酸の応用

ヒアルロン酸 (hyaluronan, hyaluronic acid, HA) is a glycosaminoglycan that occurs naturally in living organisms. It was first isolated from the vitreous humor of cattle in 1934 by Karl Meyer and John Palmer of Columbia University in the United States. They named it “hyaluronic acid”, which comes from the words “hyalo-oid” and “uronic acid” [1]. Later, Endre Balazs coined the term “hy aluronan” in 1986 to name hyaluronic acid in line with the international naming convention for polysaccharides, to cover various molecular forms (including acid and salt forms) [2]. Hyaluronic acid is an important component of the cell matrix and various tissues, and has a variety of important physiological functions, such as regulating cell proliferation, migration and differentiation; natural moisturizing; lubricating joints to protect cartilage; regulating protein synthesis; regulating inflammatory responses; regulating immune function; promoting wound healing, etc.

ヒアルロンacid's unique viscoelasticity, biocompatibility and degradability have led to its wide application in the biomedical field, including as an ophthalmic surgical aid, an anti-adhesion agent after surgery, a wound healing and regeneration aid, a drug carrier, a tissue engineering scaffold, etc. This article describes the structure, properties and chemical modification methods of hyaluronic acid, and discusses the current status of its application in the biomedical field. ヒアルロンacid'のユニークな構造特性と優れた特性は、それが生物医学分野で非常に有望なアプリケーションを持っていることを意味します。このレビューの目的は、研究者の育成です'それの包括的なアカウントを提供することにより、ヒアルロン酸への関心、および新規ヒアルロン酸バイオメディカル材料の設計のためのいくつかのガイダンスを提供します。

1ヒアルロン酸の構造、性質、生理機能

1. 1ヒアルロン酸の化学構造

Hyaluronic acid is a member of the glycosaminoglycan (also known as mucopolysaccharide) family. Like other glycosaminoglycans, hyaluronic acid is a high-molecular-weight linear polysaccharide composed of repeating disaccharide units of aminohexose and hexuronic acid. However, it is the only non-sulfated glycosaminoglycan and the only glycosaminoglycan that is not covalently linked to nuclear proteins to form proteoglycans. Unlike most glycosaminoglycans, hyaluronic acid is synthesized on the cell membrane via membrane proteins, rather than via the cell' sゴルジ装置[3]。自然の二糖类部ヒアルロン酸はD-glucuronic酸N-acetyl-D-glucosamine人で構成され、不健全化の可能性について詳細βによって−1、3 glycosidic債券と二糖类部深いβ1、4 glycosidic債券すなわち[(1→3)-β-D-GlcNAc -(1→4)-β-D-GlcUA -](図1参照)に及ぶ分子量10 7ダていた[4]。糖質も採用β-configurationをヒドロキシ、carboxyl、acetamido hydroxymethyl団体e-bonding配置となりをヒアルロン酸とても安定した精力的なのである。

1. 2ヒアルロン酸の性質

Hyaluronic acid is a white, amorphous solid with no smell. It is highly hygroscopic, soluble in water but insoluble in organic solvents. のhydrophilic groups in the molecular structure of hyaluronic acid are all in the parallel positions of the sugar rings, while the hydrophobic hydrogen atoms form a hydrophobic region in the axial direction. Due to the hydrogen bonding between the monosaccharide molecules in the molecular chain, the hyaluronic acid molecular chain forms a rigid columnar helical structure in space. In an aqueous solution, the hyaluronic acid molecules form an expanded, random coil structure. At lower concentrations, these hyaluronic acid chains also entangle with each other to form a continuous three-dimensional network structure with unique rheological properties. Water molecules are fixed in the network formed by hyaluronic acid molecules through hydrogen bonds and are not easily lost. Studies have shown that hyaluronic acid can adsorb about 1000 times its own weight in water, making it the best natural water-retaining substance found in nature. A 1% solution can form a gel, but it is easily fluid under pressure and can pass through the narrow passage of an injection needle. It is a pseudoplastic material. The extraordinary rheological properties of hyaluronic acid solutions make them ideal lubricants, capable of separating the surfaces of most tissues and allowing them to slide along each other.

1. 3 .ヒアルロン酸の分解

The degradation of hyaluronic acid in the body can be seen as a depolymerization process in which glycosidic bonds break, mainly through enzymatic hydrolysis and free radical degradation. The enzymatic degradation of hyaluronic acid in the body is mainly carried out by the hyaluronidase family, which has six members: HYAL-1, HYAL-2, HYAL-3, HYAL-4, HYAL-P1 and PH-20 [5]. Among them, the two most active enzymes are HYAL-1 and HYAL-2. HYAL-2 (located on the cell membrane) cleaves high molecular weight HA (>1MDa) into fragments of 20kDa. HYAL-1 (located in lysosomes) then cleaves these fragments into tetroses, which are further converted into monosaccharides by the action of other enzymes (e.g. β-glucuronidase, β-N-acetylglucosaminidase). Since these degradation products are natural substances that are present in the human body, they can participate in the body'の独自の除去プロセス。一方、組織の炎症などによって生成されるフリーラジカルもグリコシド結合を切断することでヒアルロン酸の酸化分解を引き起こします。ヒアルロン酸の異化は、in situ(例えば、細胞外マトリックス)、細胞内、リンパ節で起こる。長鎖ヒアルロン酸は酵素とフリーラジカルによってその場で分解され、より小さなヒアルロン酸オリゴ糖を生成します。これらのオリゴ糖は細胞内やリンパ節で代謝され、最終的に循環系に入り、肝臓や腎臓で除去される[6]。

1. 4ヒアルロン酸の生理機能

Hyaluronic acid is an important component of the extracellular matrix. In the past, hyaluronic acid was considered to be a simple space-filling substance, and it was only gradually that its importance was recognized. Due to its high water absorption, the primary role of hyaluronic acid in the human body is structural support and moisture retention. It provides lubrication and shock absorption for cells and other extracellular matrix components (including collagen and elastin), while regulating the water balance of tissues and providing a favorable environment for cell migration and proliferation. Hyaluronic acid also has a large number of negatively charged carboxyl groups on its backbone, which act as ion exchangers and can regulate the concentration of cations around cells. In addition, hyaluronic acid also acts as a signaling molecule, participating in cell signaling and regulating various cell activities, including cell proliferation, migration, differentiation, and adhesion, by binding to various protein receptors on the extracellular matrix and cell membrane. Thus, it plays a role in regulating physiological functions of the body, For example, hyaluronic acid can promote the aggregation of white blood cells at the site of inflammation through binding to the CD44 receptor, thereby promoting the body'の免疫抗炎症効果[7]。

This signal-regulating effect of hyaluronic acid is related to its molecular weight, with hyaluronic acids of different molecular weights triggering different signal pathways. High molecular weight hyaluronic acid exhibits anti-angiogenic, scar-inhibiting and anti-inflammatory effects, while low molecular weight hyaluronic acid (<100kDa) exhibits the opposite effects, promoting inflammation, immune stimulation, scar formation and angiogenesis [8]. The cause of this difference is still uncertain. One hypothesis is that 高分子量ヒアルロン酸 has the effect of aggregating receptor proteins on cell membranes, while low molecular weight hyaluronic acid does not have this effect [9], thus causing differences in receptor activity and resulting in different physiological functions.

Hyaluronic acid is an intelligent moisturizing factor that can adjust its water absorption according to the relative humidity of the surrounding environment, regulating the water balance of cells and tissues. In the skin, these highly moisturizing hyaluronic acids form an extracellular colloidal matrix with a high water content together with collagen and elastin, giving the skin resilience and elasticity. At the same time, hyaluronic acid also has the effect of scavenging free radicals. As mentioned above, free radicals can oxidize and degrade hyaluronic acid, and hyaluronic acid uses this degradation reaction to remove free radicals in the body through its own rapid metabolism.

ヒアルロン酸は滑液の主成分でもあり、その高い粘弾性は関節の保護に重要な役割を果たしています。これは、歩行などの低衝撃周波数で粘性液体であり、組織間の摩擦を減少させる。応力の衝撃を緩和する、走行などの高い衝撃周波数で弾性液体;また、荷重をかけたゲル状エラストマーが緩衝材の役割を果たし、関節への圧力を軽減する[10]。

Hyaluronic acid also plays a role in promoting tissue wound healing and is a recognized major compound in this process. It plays an important role in the activation and regulation of immune responses, the promotion of angiogenesis, and cell proliferation and migration. During the inflammatory phase, high molecular weight hyaluronic acid increases, absorbing water to expand and produce a porous scaffold suitable for cell migration, inhibiting the migration of neutrophils, and reducing the inflammatory response. During the proliferation phase, hyaluronan oligosaccharides promote angiogenesis and the migration of fibroblasts to the wound tissue, where they construct a new extracellular matrix. During the reconstruction phase, hyaluronic acid regulates scar formation [11].

2ヒアルロン酸の工業生産

Hyaluronic acid is widely found in the cell matrix and lubricating fluid of various tissues in animals, including human umbilical cords, joint synovial fluid, skin, thoracic lymphatic fluid, vitreous humor, and rooster combs. The rooster comb is currently the animal tissue found to have the highest hyaluronic acid content (see Table 1) [4]. The extraction process of hyaluronic acid generally involves a complete set of processes such as homogenization, extraction, precipitation, and impurity removal of these freshly collected hyaluronic acid-rich tissues to finally obtain hyaluronic acid with high purity. Although the extraction method has a simple process flow, it is restricted by the limited source of raw materials, low efficiency, and high cost, and has gradually been replaced by the fermentation method.

The use of microbial fermentation to prepare hyaluronic acid first appeared in the 1970s, but it was not until 1985 that Shiseido in Japan first reported the use of Streptococcus fermentation to produce hyaluronic acid. This led to the development of the biological fermentation method, which gradually replaced the traditional animal tissue extraction method and has become the mainstream international method of hyaluronic acid production today [12]. Currently, the commercially produced hyaluronic acid strains include Streptococcus and Bacillus subtilis.

3ヒアルロン酸の化学修飾

居住時間は純粋なヒアルロン酸人体は比較的短く、皮膚や関節に注射してから24時間未満の半減期があります[13]。これは生物医学分野での応用を大きく制限している。しかし、ヒアルロン酸は、カルボキシル基、ヒドロキシル基、および脱アセチル化によって露出したアミノ基を含む複数の活性基のために、さらに化学的修飾を受けることができ、より優れた機械的強度、レオロジー特性、および酵素加水分解に対する耐性などを与えることができます。

3.1 Carboxyl修正

3.1.1ハッシュAmidation反応

The carboxyl group of hyaluronic acid can be activated by carbodiimides, 2-chloro-4,6-dimethyl-1,3,5-triazine (CDMT), 2-chloro-1-methyliodopyridine (CMPI), 1, 1,1'-カルボニルジイミダゾール(cdi)などを活性化させ[14~17]、アミノ化合物と効率よく反応させてアミド結合を形成させる(図2参照)。反応機構は、edcの活性化カルボキシル基がo-アセチルイソウレア中間体を形成し、次にアミノ基が求核攻撃を行いアミド結合を形成する。O-acetylからisourea中間にもなりやすい快速並び替えと反応すると、水は厩の副産物のN-acetylurea N-acetylureaの形成を促进を防ぐためN-succinimide (NHS)またはhydroxybenzotriazole (HOBT)を形成するときに加える活性化馬屋hydrolysis-resistant中間(図3参照)[18]。

On the other hand, the optimum pH for the EDC activation reaction is 3.5~4.5, and amino groups have a high pK a value. Under these pH conditions, the nucleophilicity of protonated amino groups is reduced, and their reactivity with activated carboxyl groups is also reduced. Replacing amino groups with hydrazides with a low pK a (pK a ≈2~3) can increase the reactivity [19]. Hyaluronic acid gels prepared with dihydrazides as cross-linking agents have stronger mechanical properties. When an excess of adipoyl dihydrazide (ADH) is used to react with hyaluronic acid, only a monofunctionalization reaction occurs, forming a stable hyaluronic acid-ADH derivative that retains the other hydrazide as a reaction site for further functionalization (see Figure 2). In practice, many hyaluronic acid-drug precursors are formed by the reaction of the hyaluronic acid-hydrazide intermediate with imine-activated drugs rather than by the reaction of hyaluronic acid itself, because the main by-product when hyaluronic acid is used directly is N-acetylurea.

3. 1. 2エステル化

In addition to reacting with amino compounds, the carboxyl group of hyaluronic acid can also undergo an esterification reaction with fatty or aromatic alcohols. The above-mentioned activating reagents can also be used to catalyze the esterification of the hyaluronic acid carboxyl group. The activated hyaluronic acid can also undergo a crosslinking reaction with its own hydroxyl groups to form a self-crosslinking gel (the crosslinking structure does not contain a crosslinking agent). In addition to esterification with alcohols, hyaluronic acid can also react with haloalkanes and epoxides to form ester bonds (see Figure 4) [20 , 21] .

3. 2ヒドロキシ修正

3. 2. 1物

Due to the presence of hyaluronidase, the half-life of natural hyaluronic acid in the human body is relatively short. Therefore, various hyaluronic acid fillers on the market generally use chemical cross-linking to improve their resistance to enzymatic hydrolysis and prolong their retention time in the body. In 1964, Laurent et al. [22] first reported the cross-linking reaction of hyaluronic acid. They used 1,2,3,4-diepoxbutane as the cross-linking agent, and the reaction occurred under strong alkaline conditions with a pH of 13-14. Currently, the cross-linking agents used by major manufacturers around the world include 1,4-butanediol diglycidyl ether (BDDE), 1,2,7,8-diepoxyoctane (DEO), divinyl sulfone (DVS), etc. (see Figure 5) [23] , are mainly used to cross-link hyaluronic acid through etherification. Etherification generally takes place under strongly alkaline conditions. Here, the hydroxyl groups undergo deprotonation (pK a ≈ 10) to form strongly nucleophilic oxygen anions, which preferentially add nucleophilically to deprotonated carboxyl groups to form ether bonds. Under acidic conditions (pH 2~4. 5), the deprotonation of the hydroxyl group is reduced, and the ester bond is mainly formed by the attack of the negatively charged carboxyl group on the epoxy group (see Figure 5) [24]. However, Tomihata and Ikada [25] found that under weak acidic and neutral conditions (pH = 4.7, 6.1, 8.0), the product is still dominated by ethers.

3. 2. 2エステル化

The ヒアルロン酸のヒドロキシ基 can also undergo esterification reactions with activated carboxylic acids, anhydrides, and active groups such as acid chlorides. For example, Coradini et al. [26] reported the use of butyric anhydride to react with the hydroxyl group on the trimethylpyridine salt of hyaluronic acid in the presence of pyridine or dimethylaminopyridine to form a hyaluronic acid-butyric acid precursor. This hyaluronic acid-butyric acid precursor drug not only retains the original pharmacological effects of butyric acid, but also promotes the uptake of butyric acid by cells and improves the effect of butyric acid in inhibiting the growth of tumor cells. In fact, hyaluronic acid-butyric acid is completely endocytosed into MCF-7 human breast cancer cells under the mediation of the CD44 receptor, showing relatively obvious tumor targeting.

3. 2. 他反応三

The hydroxyl groups of hyaluronic acidまた、グルタルアルデヒドと架橋反応してヘミカリックスを形成するなど、他の反応も起こすことができる[26]。この反応はアルデヒド基を活性化し、反応を触媒するために酸性条件を必要とする。しかし、結果として得られるヘミケタールは酸性条件下で加水分解されやすいため、架橋生成物を安定化させるためには反応の最後に中和が必要である[27]。さらに、ヒアルロン酸のヒドロキシ基も臭化シアンによって活性化され、アミン化合物と水相で反応してカルバメートを形成することができます[28]。

3. 3番目のアメーバとアメーバ

The free amino group formed by deacetylation of the acetyl group on hyaluronic acid can also be used as an active site for modification reactions. It can react with activated carboxylic acids to form amide compounds, or even undergo self-crosslinking with its own carboxyl group to form a gel. However, deacetylation, even under mild conditions, can cause degradation of hyaluronic acid [29], so this method is generally not used for hyaluronic acid modification.

3. 4   複雑な修正

Hyaluronic acid can also be used in combination with other materials to take advantage of their respective advantages and compensate for their deficiencies. For example, hyaluronic acid and chitosan can be combined to form nanoparticles through electrostatic interaction, which can be used to load papain and form new surfactants[30]; hyaluronic acid and gelatin can be combined through emulsification-coagulation, and smooth, wrinkled and porous microspheres can be obtained by different post-treatment methods [31]; the combination of hyaluronic acid and hydroxypropyl methyl cellulose can improve the resistance of the gel to enzymatic hydrolysis [32, 33]; the combination of hyaluronic acid and collagen will give it better mechanical properties.

3. 5金属団地

Hyaluronic acid is rich in O and N atoms, and can form coordination bonds with a variety of metal ions, such as Fe3+, Zn2+, Cu2+, Ni2+, etc. Coordination changes the structure of hyaluronic acid in solution and gives it more biological functions[34]. For example, Curiosin gel from Gedeon Richter is a complex of hyaluronic acid and Zn2+, which changes the structure of hyaluronic acid from a random coil to a spherical structure through coordination, reducing the thickness of the bound water molecule layer and making the bond more stable. Clinical trials have shown that this gel can effectively promote wound healing and prevent wound infection.

4ヒアルロン酸とその誘導体の生物医学的応用

Hyaluronic acid's unique properties make it suitable for a wide range of biomedical applications. Balazs [35] divides the clinical applications of hyaluronic acid and its derivatives into five categories.

(1)粘度外科:脆弱な組織を保護し、眼科手術などの外科手術のためのスペースを提供する;

(2) viscoaugmentation:皮膚、括約筋、声帯、咽頭組織などの組織空間の充填と拡張;

(3)粘度分離:手術や外傷によって損傷した結合組織の表面を分離し、接着や過度の瘢痕化を防止する。

(4)粘性補給(粘性補給):関節炎の潤滑油を交換するなど、組織液を交換または補充して痛みを和らげる;

(5)粘性保護(ビスコース保護):健康な組織表面を乾燥や有害な環境の影響から保護し、組織表面の治癒を促進する。

4.1眼科

Hyaluronic acid is a major component of the eye'の硝子体のユーモアとは、主に白内障の手術や眼内レンズの移植などの操作中に失われた硝子体のユーモアを交換するために眼科手術で使用されます。一方、ヒアルロン酸は、角膜上皮を保護し、機械的衝撃を緩衝し、目の前室の適切な深さと形状を維持し、眼内組織を保護し、硝子体脱を防止し、手術を容易にするために、眼科手術において粘弾性保護剤としても使用されています[36]。ヒアルロン酸はドライアイ症候群の治療薬の主成分でもあります。それは効果的に涙膜破裂時間を延長し、ドライアイ症候群患者の瞬きの数を減らし、乾燥、刺激、かゆみ、および痛みの症状を緩和することができます。

4. 2肌を願いたい

Hyaluronic acid is a natural moisturizer that is widely found in skin tissue, and its concentration can reach 2. 5g/L. As we age, the amount of hyaluronic acid in the skin gradually decreases, leading to dehydration of the dermis, deepening of wrinkles, and loss of elasticity. Hyaluronic acid is widely used as a skin filler to treat facial aging due to its high viscoelasticity, plasticity, biodegradability, good biocompatibility, and lack of species specificity. According to statistics from the International Society of Aesthetic Plastic Surgery (ISAPS), the number of cases in which hyaluronic acid fillers are used ranks second among minimally invasive cosmetic treatments, after botulinum toxin. However, the natural hyaluronic acid in the human body has a very short maintenance cycle and cannot guarantee the long-term effect of filling and modification. Therefore, physical or chemical cross-linking protection methods are generally used to increase the resistance of hyaluronic acid to enzymatic hydrolysis and prolong its retention time in the body.

4. 3抗接着と創傷治癒

Postoperative tissue adhesion is a major problem in surgical procedures, which can lead to serious long-term clinical complications, affecting the results of surgical procedures and causing pain and inconvenience to patients. A large number of studies have shown that hyaluronic acid plays an important role in preventing adhesion and promoting wound healing. The mechanism of hyaluronic acid in preventing tissue adhesion mainly includes: (1) separating tissues through physical shielding, which can also shield inflammatory mediators and bacteria, thus playing a protective role; (2) promoting the dissolution of blood fibrin, while stimulating the expression of CD44 receptors to promote the proliferation of mesenchymal cells; (3) enhancing the function and activity of macrophages, regulating collagen synthesis, reducing the deposition of blood fibrin, promoting wound healing and reducing scar formation; (4) forming a protective film on the tissue surface to reduce mechanical damage and provide lubrication and moisture; (5) absorbing and expanding to compress bleeding points and suppress bleeding[38] .

Epidermal growth factor (EGF), fibroblast growth factor (bFGF), etc. are now widely used in skin wound repair, but these products are generally in the form of freeze-dried powder, which needs to be stored in the refrigerator before use, and has a very short half-life, so it needs to be applied repeatedly every day. Yamamoto et al. [39] reported a dual-layer wound dressing formed by high-molecular-weight and low-molecular-weight hyaluronic acid, where the high-molecular-weight cross-linked hyaluronic acid forms the upper layer of the supplement and the low-molecular-weight hyaluronic acid, arginine, vitamin C derivatives and EGF form the lower layer. Experimental results show that this wound supplement can maintain the activity of EGF and promote the release of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF).

4. 4関節炎

Hyaluronic acid is the main component of articular cartilage and synovial fluid. In normal, healthy joints, movement can be carried out almost friction-free and pain-free. However, when joint diseases such as osteoarthritis or rheumatoid arthritis occur, the concentration of hyaluronic acid in the synovial fluid decreases significantly, the molecular weight decreases significantly, and the cartilage is also degraded and destroyed, causing the joint movement to become stiff and pain due to bone-on-bone friction. Injecting exogenous high molecular weight hyaluronic acid into the joint restores the synovial fluid to a normal state and promotes the gradual natural repair of cartilage. At the same time, the injected hyaluronic acid also improves the biological environment of the joint cavity, promotes the synthesis of endogenous hyaluronic acid, and improves joint function. However, because the half-life of hyaluronic acid in the body is short, repeated and frequent injections are required for the treatment of joint lesions, which increases the patient&#苦しん39;s。最近、jordanら[40]は、ヒアルロン酸とキトサンの混合物から作られた新しいタイプのゲルを報告した。キトサンの添加は、ヒアルロン酸の抗分解能力を高めるだけでなく、治療効果も向上させた。この研究は、関節疾患の治療のための粘性ヒアルロン酸サプリメントを改善するための新しい方向性を提供します。

In recent years, there has been some debate about whether this viscoelastic supplement therapy is effective in treating arthritis. The second edition of the “Evidence-Based Guidelines for the Treatment of Knee Osteoarthritis” issued by the American Academy of Orthopaedic Surgeons in 2013 clearly states that hyaluronic acid is not recommended for the treatment of symptomatic knee osteoarthritis. They believe that although many studies have shown that the effect of high molecular weight hyaluronic acid on the treatment of osteoarthritis is statistically different compared to the control, this difference does not meet the minimum clinically important difference (MCII) standard and therefore does not have a clinically significant difference.

4. 5麻薬キャリア

Hyaluronic acid has the potential to be used as a drug carrier due to its good biocompatibility, high hydrophilicity, high viscoelasticity, degradability and specific binding to cell surface receptors (such as CD44 and RHAMM). On the other hand, from the chemical structure of hyaluronic acid, it has multiple reaction sites, including carboxyl groups, hydroxyl groups and acetylated amino groups, which can be used to construct drug precursors and carriers using a variety of chemical modification methods. At present, hyaluronic acid and its derivatives have been used to construct drug delivery systems for a variety of drugs, including anti-inflammatory drugs, anti-tumor drugs, protein peptide drugs and gene drugs, which can significantly prolong the blood circulation residence time of drugs, increase cellular uptake, improve bioavailability, reduce the amount of drug administered, and reduce adverse reactions [8, 41]. Zhong et al. [42] reported a reduction-sensitive, reversibly cross-linked hyaluronic acid nanoparticle composed of a hyaluronic acid-lysine-lipoic acid (HA-Lys-LA) covalent bond, which is cross-linked by a disulfide bond under the catalysis of 1, 4-dithio-D,L-threitol (DTT) catalysis, the drug doxorubicin (DOX) is cross-linked by disulfide bonds to improve the residence time of the drug under physiological conditions.

This nanocarrier specifically binds to the CD44 receptor overexpressed on the surface of MCF-7 human breast cancer cells resistant to DOX through hyaluronic acid located on the surface, thereby increasing the cellular uptake of the drug. The nanocarrier then swells and releases the drug by catalysing the breakage of the disulfide bond by glutathione, which is overexpressed in tumor cells, effectively inhibiting tumor growth (as shown in Figure 6). Park et al. [43] also reported the use of a similar drug carrier for siRNA transfection. They designed and synthesized a hyaluronic acid-poly(dimethylaminoethyl methacrylate) (HPD) grafted polymer as a siRNA delivery vehicle, and cross-linked it via a disulfide bond. In vitro experiments have shown that the cross-linked siRNA complex (C-siRNA-HPD) is more stable and can be more effectively taken up by melanoma cells overexpressing CD44, thereby improving siRNA transfection efficiency. In vivo experiments have shown that after systemic administration in mice, C-siRNA-HPD selectively accumulates in tumors, demonstrating its tumor targeting properties.

4. 6細胞組織工学

Tissue engineering is a new interdisciplinary subject that emerged in the 1980s and has become a research hotspot in tissue and organ regeneration medicine in recent years. Hyaluronic acid is an important component of many tissues in the human body and is a major component of the extracellular matrix. It affects cell proliferation, migration and differentiation, and promotes wound healing, making it an ideal raw material for tissue engineering. However, the weak mechanical properties, high swelling properties, smooth surface structure and lack of resistance to enzymatic hydrolysis of hyaluronic acid gels also limit their application in tissue engineering. Therefore, in order to improve the possibility of using them as scaffolds for tissue engineering, necessary chemical modifications are required to compensate for their deficiencies. One good method is to select other biomaterials for compounding, which can combine the advantages of multiple materials to complement each other' s及ばなかった点です例えば、アルギン酸ナトリウムとヒアルロン酸は架橋して多孔質の複合ゲルを形成することができます。ポリマーの濃度と2つの多糖類の比率を調整することによって、複合ゲルの膨張速度、多孔性、酵素加水分解に対する耐性を制御することができ、それによって細胞の付着と増殖のための良好な生物学的環境を提供することができる[44]。

4. 7バイオミメティックス

High-throughput screening of drugs is generally done through 2D in vitro cytological evaluation, but this method differs greatly from the actual results in vivo. Using 3D scaffolds to simulate the cell microenvironment is more in line with actual conditions. Hyaluronic acid is an important component of the extracellular matrix, and using it to construct a 3D culture medium will be more suitable for mimicking the in vivo growth environment of cells. Hyaluronic acid itself is negatively charged, which hinders cell adhesion, so it needs to be combined with other biomaterials to promote cell adhesion. Zhang et al. [45] used hyaluronic acid and chitosan to construct a 3D porous scaffold material for mimicking the extracellular matrix microenvironment of U-118MG human malignant glioma cells as a 3D culture medium for high-throughput screening of anti-tumor drugs. Compared with 2D culture medium, hyaluronic acid-chitosan scaffold culture medium can promote the formation of tumor spheroids and upregulate the expression of CD44, nestin, Musashi-1, GFAP and HIF-1α proteins.

5結論

Hyaluronic acid has a history of more than 60 years since it was first used in human medicine in the late 1950s. Due to its special rheological properties and physiological functions, hyaluronic acid is widely used in the biomedical field. So far, the research on the design of new hyaluronic acid derivatives has made great progress, and more and more hyaluronic acid products have been developed to fill the gaps in biomedical applications. This paper reviews the structural properties, synthetic modification and biomedical applications of hyaluronic acid. However, there are still many unanswered questions about the physiological functions of hyaluronic acid. At present, commercially available hyaluronic acid biomaterials still have certain defects that require further improvement to promote the wider application of hyaluronic acid in the biomedical field.

参照

[1]マイヤーk パーマーJWでる  J Biol lg化学 1934年 107: 629 ~ 634。

[2] balazs ea、 ローランTC、 Jeanloz RW。  逃れJ 1986年 235: 903 ~ 903。

[3] weigel ph, Hascall VC、 Tammi M。  J Biol lg化学 1997年 272: 13997 ~ 14000。

[4]コーガンg Soltes L, 厳しいR。 P Gemeinerです。  Biotechnol Lett、 2007年 29日: 17 ~ 25。

[5] csoka ab 霜GIに対し、 厳しいR。  マトリクスBiol 2001年 20: 499 ~ 508。

[6] De K Boulle Glogau R, 河野T, ネイサンM A Tezel Roca-Martinez J-X、 Paliwal S Stroumpoulis D  Dermatol Surg、 2013年 39: 1758年~ 1766の養子となる。

[7] termeer c, Sleeman金氏 サイモンJC』でした  トレンドImmunol 2003年 その24: 112 ~ 114。

[8] schante ce, 佐伯G Herlin C Vandammeタスクフォース(TF)。  Carbohydr Polym、 2011年 85: 469 ~ 489。

【9位】江d 梁J ファンJ 禹相虎(S 陳S 羅Y Prestwich上手い Mascarenhas MM Garg HG、 クインダ、 ホーマーRJ ゴールドスティンDR Bucala R, 李)PJ Medzhitov R, PW貴族。  Nat Medです 2005年11月 1173年(1179年)~。

【10】凌peixue、何yanli、張清。^『食と薬』2005年、7:1 ~ 3:3。

【11】jin yan, li dawei, zhu meihua, chen jianying。^「food and drugs, 2014, 16/373 ~376」。food and drugs . 2014年3月16日閲覧。

【12】崔淵、段謙、李延徽長春科学技術大学紀要(自然科学編),2011,34:101~106。

[13]ブラウン父は言った ローランUBG、 迷う余地JREん  Exp Physiol、 1991年 76 125 ~ 134。

[14] Danishefsky I, Siskovic E  Res Carbohydrい、 1971年(昭和46 16: 199 ~ 205。

【15位】A Magnani Rappuoli R, Lamponi S Barbucci R・  polym adv technol 2000年 11: 488 ~紀元前495。

[16] Kフォルケ・ベリイマンで Elvingson C Hilborn J Svensk G バウデンTない  生体高分子の 2007年 8: 2190 ~ 2195。

〔17〕casta diva D Topai。  WO2000001733A1。 2000.

[18] Bulpitt P Aeschlimann D  j biomed mater res, 1999年 47: 152 ~ 169。

[19] Pouyani T, Prestwich委ねます"  Bioconjugate lg化学 1994年 5: 339 ~ 347だった。

【20 Pelletier S】 ヒューバート・プリムラーによってP Lapicque F Payan E Dellacherie E  Carbohydr Polym、 2000年 43系統 343 ~ 349。

[21] Bencherif SA, A Srinivasan Horkay F Hollingerジョー K Matyjaszewski ミッチェル・リヴィングストン・ウォッシュバーン番  生体材料を使い、 2008年 29日: 元文4年(1739年)~ 1749。

[22]ローランTC、 K Hellsing Gelotte B  スカンジナビア化学協会 1964年 18: 274 ~ 275よーい

【23】君健、瑞枝李。cn 102321258bするものである。2012.

[24] de belder an Malson T  US4886787A。 1985.

[25]やがてK Tomihata 「いかだ」ちょうだい  生体材料を使い、 1997年 18: 189 ~ 195。

[26] Coradini D Pellizzaro C Miglierini G Daidone MG、 Perbellini。  Int J がん 1999年 81: 411 ~ 416。

【27】コリンズ氏MN Birkinshaw C  j appl polym sci, inc。 2007年 104: 3183 ~ 3191白岩。

【28】表にMlcochova P Bystricky S シュタイナーB Machova E Koos M Velebny V Krcmar M。  Biopolymers、 2006年 82: 74 ~ 79

[29] Crescenzi V A Francescangeli Segreアル、 Capitani D Mannina L, Renier D 先生を見つけDなぁ。  Macromol Biosci、 2002年 2: 272 ~ 279だった。

[30] zhao d, wei w, zhu y, sun j, hu q, liu x。  ^『仙台市史』通史編、仙台市、2015年、558 - 567頁。

【31】zhou z, he s, huang t, peng c, zhou h, liu q, zeng w, liu l, huang h, xiang l, yan h。  ^ポリム・ブル、2015年、72:713 ~723頁。

【32】健君、李瑞智。CN 102492180Bするものである。2014.

【33】健君、李瑞智。CN 102911380Aするものである。2013.

[34]金燕、凌peixue、張天民。^『日本生物工学会誌』日本生物工学会、2008年、29 - 29頁。

[35] garg hg, hales ca . chemistry and biology of hyaluronan, uk: elsevier, 2004, 415-455。

[36] zhang lei, wu di, sun wei, sun junde。2006年日刊微生物学、26:100-103。

【37】龐蘇丘、周金生、陳秋夏。^アポロドーロス、2003年5月15日、252頁。

[38]凌peixue、関華史。中国医薬ジャーナル、2005年、40:1527-1530。

[39]山本、 清水N 「黒柳Y。  J Artif機関 2013年 16: 489 ~ 494。

[40] Kaderli S Boulocher C Pillet E Watrelot-Virieux D Rougemontアル、 ロジャーT, Viguier E Gurny R, Scapozza L, ジョーダンO。  int・j・ファム 2015年 483: 158 ~ 168。

[41] zhang wei, yan cui ' e。化学進歩、2006年、18:1684~1690。

[42] zhong y, zhang j, cheng r, deng c, meng f, xie f, zhong z . j controlled release, 2015, 205: 144 - 154。

[43] yoon hy, kim hr, saravanakumar g, heo r, chae sy, um w, kim k, kwon i c, lee jy, lee ds, park jc, park jh。  ^ a b c d e f g h i j controlled release, 2013, 172: 653~661。

[44] chen y h, li j, hao y b, qi j x, dong ng, wu c l, wang q . j appl polym sci, 2015, 132: 41898。

[45] florczyk sj, wang k, jana s, wood dl, sytsma sk, sham jg, klevit fm, zhang m . biomaterials, 2013, 34: 10143 - 10150。